Market Movers (8-K)
OQB
Guided Therapeutics, Inc. has entered into a securities purchase agreement to raise $535,000 through a private placement of common stock and warrants.
Capital raise
OQB
Guided Therapeutics, Inc. has successfully raised $300,000 through a private placement of common stock and warrants to institutional investors, including a board member.
Capital raise
Quarterly Earnings (10-Q)
See all →OQB
Guided Therapeutics, Inc. reported its Q2 2026 financial results, highlighting continued operating losses and a substantial accumulated deficit, while also noting progress in its LuViva device clinical trials and ongoing capital-raising efforts.
Worse than expected
Capital raise
OQB
Guided Therapeutics, Inc. filed its Q1 2026 Form 10-Q, detailing financial performance, operational updates, and a significant promissory note extension with its CEO.
Capital raise
Worse than expected
OQB
Guided Therapeutics reported increased net losses and negative working capital, with key regulatory approvals for its LuViva device facing delays in China and potential impacts from a U.S. government shutdown.
Delay expected
Worse than expected
Capital raise
OQB
Guided Therapeutics reported a widened net loss and deepening accumulated deficit in Q2 2025, highlighting significant liquidity challenges despite progress in regulatory approvals for its LuViva device.
Delay expected
Worse than expected
Capital raise
OQB
Guided Therapeutics enters into a securities purchase agreement for a $149,500 convertible note to bolster working capital as it navigates commercialization and regulatory pathways for its LuViva device.
Capital raise
Worse than expected
OQB
Guided Therapeutics reports its Q3 2024 financials, highlighting ongoing efforts in product development and regulatory approvals, while navigating financial challenges.
Worse than expected
Capital raise
Annual Reports (10-K)
OQB
Guided Therapeutics' 10-K filing reveals ongoing financial challenges and efforts to commercialize its LuViva cervical cancer detection device while pursuing regulatory approvals and strategic partnerships.
Delay expected
Capital raise
Worse than expected
OQB
Guided Therapeutics, a medical technology company, released its 2023 annual report, highlighting its focus on commercializing the LuViva cervical cancer detection device and navigating financial challenges.
Delay expected
Capital raise
Worse than expected
Insider Trading (Form 4)
See all →OQB
Director Richard P. Blumberg significantly increased his common stock holdings in Guided Therapeutics through warrant exercises and preferred stock conversions.
Capital raise
OQB
Director Alan Grujic acquired 110,000 stock options for Guided Therapeutics Inc. (GTHP) with an exercise price of $0.29, vesting over several years.
OQB
John E. Imhoff, a Director and 10% owner of Guided Therapeutics Inc., reported several transactions including stock option exercises and convertible note conversions.
OQB
Guided Therapeutics Inc. reports that Director James Michael C acquired stock options for 110,000 shares, with vesting scheduled through March 2029.
OQB
GUIDED THERAPEUTICS Director John E. Imhoff significantly increased his beneficial ownership in the company through multiple conversions of debt and preferred stock into common shares and warrant exercises.
Capital raise
OQB
GUIDED THERAPEUTICS Director Michael C. James increased his direct ownership of common stock and extended the expiration of other warrants through recent transactions.